ADVM Average Annual Return Since 2014
Growth of $10,000.00
Without Dividends Reinvested Into ADVM

Also see:
ADVM stock yearly return 2015
ADVM stock yearly return 2016
ADVM stock yearly return 2017
ADVM stock yearly return 2018
ADVM stock yearly return 2019
ADVM stock yearly return 2020
ADVM stock yearly return 2021
ADVM stock yearly return 2022
ADVM stock yearly return 2023
ADVM YTD return
Compare ADVM average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 08/01/2014
End date: 05/17/2024
Start price/share: $251.60
End price/share: $8.04
Dividends collected/share: $0.00
Total return: -96.80%
ADVM Average Annual Return: -29.63%
Starting investment: $10,000.00
Ending investment: $319.45
Years: 9.80

ADVM average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Adverum Biotechnologies is a clinical-stage company focused on establishing gene therapy as a standard of care for ocular diseases. Co.'s main product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection. The ADVM average annual return since 2014 is shown above.

The Average Annual Return on the ADVM average annual return since 2014 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether ADVM average annual return since 2014 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the ADVM average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree ADVM Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Adverum Biotechnologies (ADVM) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

AEMD Average Annual Return
AEZS Average Annual Return
AFIB Average Annual Return
AGEN Average Annual Return
AGIO Average Annual Return
AGL Average Annual Return
AGRX Average Annual Return
AHCO Average Annual Return
AIMD Average Annual Return
AIQ Average Annual Return
More Healthcare companies »


ADVM Average Annual Return Since 2014 | | Copyright © 2021 - 2024, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.